Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Analysis of renal response data in the prospective REMNANT study in TE NDMM patients suggests Revlimid as part of induction therapy in renal impairment provides good safety and efficacy even without adjustment for renal function.”
Title: Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
Authors: Frida Bugge Askeland, Vilhelm Hauge Bugge, Anne-Marie Rasmussen, Anna Lysén, Einar Haukås, Magnus Moksnes, Anette L. Eilertsen, Galina Tsykunova, Birgitte Dahl Eiken, Nils Morten Leknes, Jürgen Rolke, Vidar Stavseth, Eivind Samstad, Randi Fykse Hallstensen, Damian Szatkowski, Ariane Aasbø Hansen, Anita Smith Nilsen, Tobias S. Slørdahl, Pegah Abdollahi, Fredrik Schjesvold
You can read the Full Article in Blood Cancer Journal.
You can find more posts featuring Robert Orlowski on OncoDaily.
